- Price
- $243.87
- Day
- -0.95%
- Mkt Cap
- $430.87B
- 52W Range
- $190.75 – $267.47
- Volume
- 2.98M
- Beta
- 0.28
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Read full article
BDF Gestion reduced its position in shares of AbbVie Inc. (NYSE: ABBV) by 10.1% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 40,006 shares of the company's stock after selling 4,498 shares during the quarter. AbbVie accounts for
Read full article
There is no end in sight for the drugmaker's dividend growth streak.
Read full article
I'm going to put our year-end call on the table before anything else. Our AbbVie (NYSE:ABBV | ABBV Price Prediction) year-end verdict is a buy, and our proprietary model sees more room to run despite the stock already sitting near record highs.
Read full article
If approved, BOTOX ® Cosmetic (onabotulinumtoxinA) would be the only neurotoxin with five aesthetic indications and the first and only approved for masseter muscle prominence in the U.S. Submission is supported by two Phase 3 studies (M21-416 and M21-417), demonstrating statistically significant improvements in masseter muscle prominence and patient satisfaction with treatment IRVINE, Calif., Aug. 4, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental Biologics License Application (sBLA) for BOTOX® Cosmetic (onabotulinumtoxinA) for the temporary improvement in the appearance of marked to very marked masseter muscle prominence (MMP) associated with masseter muscle activity in adults.
Read full article
First National Bank of Mount Dora Trust Investment Services lessened its holdings in shares of AbbVie Inc. (NYSE: ABBV) by 6.3% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 42,721 shares of the company's stock after selling 2,870
Read full article
On June 29, AbbVie Inc. stock reached a 52-week high of $267.47. But over the past five days, its shares have fallen 6.2% despite strong Q2 earnings. Rinvoq sales grew 24.5% YoY and 19.2% quarter-over-quarter to about $2.53 billion in Q2.
Read full article
Your portfolio could be paying you quarterly income right now from three companies that have raised their dividends for decades straight, but the next ex-dates are approaching fast and missing them means waiting another quarter to collect.
Read full article
AbbVie raises 2026 revenue guidance on Skyrizi, Rinvoq and neuroscience growth, while the Apogee deal trims EPS guidance and lifts R&D spending.
Read full article
The headline numbers for AbbVie (ABBV) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read full article
AbbVie (ABBV) came out with quarterly earnings of $3.65 per share, beating the Zacks Consensus Estimate of $3.64 per share. This compares to earnings of $2.97 per share a year ago.
Read full article
Despite some mid-week turbulence, we're trading fairly even with where we were as of mid-day Monday.
Read full article